Prognostic Role of MTAP Loss in Cholangiocarcinoma
- 1 July 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400842
Abstract
PURPOSE: Methylthioadenosine phosphorylase ( MTAP ) loss is a common genomic event in cancer and is associated with an immunologically cold phenotype. Recent research has highlighted a synthetic lethality of MTAP loss when combined with PMRT5 or MAT2A inhibition. Although contemporary somatic genomic testing now routinely includes MTAP status, the clinicogenomic characteristics of MTAP loss in cholangiocarcinoma (CCA) remain largely undefined. In this study, we examine the genomic profiles, clinical features, and survival outcomes of MTAP loss CCA. METHODS: This is a single-center retrospective cohort study of patients with CCA from December 2017 to January 2024. Somatic genomics alterations were assessed using targeted next-generational sequencing with FoundationOne CDx. Patient demographics, tumor characteristics, treatment history, and overall survival (OS) were retrospectively collected. Genomics coalterations were assessed using the Fisher exact test. Multivariate Cox proportional hazards regression analysis was used to assess the relationship between MTAP status and OS. RESULTS: Among 94 CCA samples, 89 were successfully sequenced, uncovering 339 genomic alterations, with MTAP loss identified in 16% of cases. It commonly co-occurred with CDKN2A and B loss (93% and 86%, respectively) and was not associated with FGF2R rearrangement, IDH1 mutation, or human epidermal growth factor receptor 2 ( ERBB2 ) amplification. Tumor mutational burden were similar between MTAP status. MTAP loss was associated with lower OS (hazard ratio, 3.95 [95% CI, 1.43 to 10.9]; P = .008) after adjustment for key covariates including age, Eastern Cooperative Oncology Group performance status, nodal stage, metastatic spread, resectability, histologic, and line of therapy. CONCLUSION: MTAP loss is common CCA, co-occurred with CDKN2A and CDKN2B loss, and was associated with poor OS. Future effort to exploit this therapeutic vulnerability in MTAP -loss CCA is critical to improve the care of this population.Keywords
This publication has 30 references indexed in Scilit:
- First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationAnnals of Oncology, 2024
- Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistanceCancer Cell, 2023
- The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerAnnals of Oncology, 2022
- Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic CholangiocarcinomaJAMA Surgery, 2021
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- Genetic Determinants of Outcome in Intrahepatic CholangiocarcinomaHepatology, 2021
- Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic OpportunitiesHepatology, 2020
- Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutationsJournal of Hepatology, 2018
- Genomic and Functional Approaches to Understanding Cancer AneuploidyCancer Cell, 2018
- MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 AxisCell Reports, 2016